Details for New Drug Application (NDA): 211751
✉ Email this page to a colleague
The generic ingredient in ESOMEPRAZOLE MAGNESIUM is esomeprazole magnesium. There are seventy-four drug master file entries for this compound. One hundred and ten suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium profile page.
Summary for 211751
Tradename: | ESOMEPRAZOLE MAGNESIUM |
Applicant: | Cipla |
Ingredient: | esomeprazole magnesium |
Patents: | 0 |
Pharmacology for NDA: 211751
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors |
Suppliers and Packaging for NDA: 211751
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 211751 | ANDA | Cipla USA Inc. | 69097-528 | 69097-528-34 | 30 FOR SUSPENSION in 1 CARTON (69097-528-34) |
ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 211751 | ANDA | Cipla USA Inc. | 69097-529 | 69097-529-34 | 30 FOR SUSPENSION in 1 CARTON (69097-529-34) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION, DELAYED RELEASE;ORAL | Strength | EQ 20MG BASE/PACKET | ||||
Approval Date: | Mar 23, 2020 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION, DELAYED RELEASE;ORAL | Strength | EQ 40MG BASE/PACKET | ||||
Approval Date: | Mar 23, 2020 | TE: | AB | RLD: | No |
Complete Access Available with Subscription